# Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

> **NCT01332656** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 154 (actual)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** Ombrabulin (AVE8062)
- **DRUG:** Placebo
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01332656
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2015-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332656, "Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01332656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*